Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Monthly dosing effective for Sanofi's alirocumab

Monthly dosing effective for Sanofi's alirocumab Despite Amgen's first-to-file status, Sanofi and Regeneron have sought to shorten their rival's lead by purchasing an FDA priority review voucher originally awarded to BioMarin Pharmaceutical for

Pharma deals during November 2014

Pharma deals during November 2014 BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its

Deal Watch table for November 2014

Deal Watch table for November 2014 Licence. 935. Prosensa / BioMarin. Drisapersen – for Duchenne muscular dystrophy.

Ziarco appoints Mike Grey to board of directors

Ziarco appoints Mike Grey to board of directors Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.

PCSK9 inhibitor alirocumab works in statin-intolerance

PCSK9 inhibitor alirocumab works in statin-intolerance BioMarin by the FDA.

[ Previous 5 results ] 10 11 12 13 14 15 16 17 18 19 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics